Haemonetics (HAE) to Release Quarterly Earnings on Thursday

Haemonetics (NYSE:HAE - Get Free Report) is scheduled to be issuing its quarterly earnings data before the market opens on Thursday, November 7th. Analysts expect the company to announce earnings of $1.09 per share for the quarter. Haemonetics has set its FY25 guidance at $4.45 to $4.75 EPS and its FY 2025 guidance at 4.450-4.750 EPS.Parties that wish to register for the company's conference call can do so using this link.

Haemonetics (NYSE:HAE - Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The medical instruments supplier reported $1.02 earnings per share for the quarter, missing the consensus estimate of $1.03 by ($0.01). The firm had revenue of $336.17 million for the quarter, compared to the consensus estimate of $335.08 million. Haemonetics had a return on equity of 21.86% and a net margin of 8.61%. The firm's quarterly revenue was up 8.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.05 EPS. On average, analysts expect Haemonetics to post $5 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Haemonetics Stock Performance

HAE stock traded down $0.87 during trading hours on Thursday, hitting $71.15. 482,264 shares of the stock were exchanged, compared to its average volume of 537,132. The company has a current ratio of 3.76, a quick ratio of 2.33 and a debt-to-equity ratio of 1.35. The firm has a market capitalization of $3.64 billion, a P/E ratio of 32.36, a P/E/G ratio of 1.16 and a beta of 0.30. The company has a 50-day simple moving average of $75.64 and a two-hundred day simple moving average of $82.94. Haemonetics has a 12 month low of $70.25 and a 12 month high of $97.97.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. Citigroup decreased their price target on Haemonetics from $94.00 to $85.00 and set a "neutral" rating on the stock in a research report on Thursday, August 22nd. BTIG Research assumed coverage on Haemonetics in a research report on Tuesday, September 10th. They issued a "buy" rating and a $112.00 price target on the stock. Barrington Research restated an "outperform" rating and issued a $108.00 price target on shares of Haemonetics in a research report on Monday, September 23rd. JMP Securities restated a "market outperform" rating and issued a $125.00 price target on shares of Haemonetics in a research report on Tuesday, August 13th. Finally, Bank of America assumed coverage on Haemonetics in a research report on Wednesday, September 11th. They issued a "neutral" rating and a $85.00 price target on the stock. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $106.14.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.